Sabutoclax

SKU: orb1685636

Description

Sabutoclax (BI-97C1) is a potent pan-inhibitor of anti-apoptotic Bcl-2 family proteins, including Bcl-xL, Bcl-2, Mcl-1, and Bfl-1. It has demonstrated pro-apoptotic activity in various cancer cell lines in vitro and has shown efficacy in xenograft tumor models in vivo, supporting its investigation in oncology research.

Research Area

Cell Biology

Key Properties

• CAS Number: 1228108-65-3
• MW: 700.78
• Purity: 99.30% (May vary between batches)
• Formula: C₄₂H₄₀N₂O₈
• SMILES: O=C(C1=C2C=C(C)[C@]([C@]3=C(C)C=C4C(C(NC[C@H](C)C5=CC=CC=C5)=O)=C(O)C(O)=CC4=C3O)=C(O)C2=CC(O)=C1O)NC[C@H](C)C6=CC=CC=C6
• Target: Bcl-2 Family
• Solubility: DMSO:93 mg/mL (132.71 mM);10% DMSO+90% Saline:3.3 mg/mL (4.71 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);Ethanol:22 mg/mL (31.39 mM)

Bioactivity

• Target IC50:
  MCL1:0.2 μM|Bcl-2:0.32 μM|Bfl-1:0.62 μM|BCL-XL:0.31 μM
• In Vivo:
  Sabutoclax (1-5 mg/kg; intraperitoneal injection; every two days for a total of 18 days) reduces the growth of M2182 tumors in nude mice.
• In Vitro:
  Sabutoclax (0.001-10 μM; 72 hours) inhibits the growth of human prostate cancer and lung cancer cell lines. Sabutoclax (0.01-1 μM; 24-48 hours) induces apoptosis in human diffuse large B-cell lymphoma cells. Sabutoclax (0-15 μM; 48 hours) upregulates the levels of pro-apoptotic proteins in chemotherapy-resistant cells.
  Read more...
• Cell Research:
  ATP-LITE assay(Only for Reference)

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Bcl-2 Family, BI-97C1, Sabutoclax

Compound Identifiers

PubChem CID

58035822